Parafibromin in the diagnosis of parathyroid carcinoma

Advances in Anatomic Pathology

Volumn 14, Issue 4, 2007, Pages 299-301

  Mangray, Shamlal ^a   Delellis, Ronald A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; GALECTIN 3; GENE PRODUCT; KI 67 ANTIGEN; PARAFIBROMIN; PROTEIN BCL 2; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

CELL CYCLE PROGRESSION; CHROMOSOME 1Q; DIFFERENTIAL DIAGNOSIS; GENE EXPRESSION; GENE INACTIVATION; GENE MUTATION; HUMAN; HYPERPARATHYROIDISM; IMMUNOHISTOCHEMISTRY; NOTE; PARATHYROID ADENOMA; PARATHYROID CARCINOMA; PARATHYROID HYPERPLASIA; PHENOTYPE; PRIORITY JOURNAL; TISSUE MICROARRAY; TUMOR SUPPRESSOR GENE;

EID: 34347352113     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e3180ca8ad0     Document Type: Note

References (17)

1. DeLellis RA, Lloyd RV, Heitz PU, et al, eds. World Health Organization Classification of Tumors Pathology and Genetics: Tumors of Endocrine Organs. Lyon: IARC Press; 2004:124-127.
2. DeLellis RA. Parathyroid carcinoma. An overview. Adv Anat Pathol. 2005;12:53-61.
3. Cryns VK, Thor A, Xu HJ, et al. Loss of the retinoblastoma tumor suppressor gene in parathyroid carcinoma. N Engl J Med. 1994;330:757-761.
4. Lloyd RV, Carney JH, Ferreiro JA, et al. Immunohistochemical analysis of the cell cycle-associated antigens Ki-67 and retinoblastoma protein in parathyroid carcinoma and adenomas. Endocr Pathol. 1995;6:279-287.
5. Farnebo F, Auer G, Farnebo L-O. Evaluation of retinoblastoma and Ki-67 immunostaining as diagnostic markers of benign and malignant parathyroid disease. World J Surg. 1999;23:68-74.
6. Erickson LA, Long J, Wollar P, et al. Parathyroid hyperplasia, adenomas and carcinomas: differential expression of p27Kip1 protein. Am J Surg Pathol. 1999;23:288-295.
7. Vargas MP, Vargas HI, Kleiner DE, et al. The role of prognostic markers (MIB-1, RB and Bcl-2) in the diagnosis of parathyroid tumors. Mod Pathol. 1997;10:12-17.
8. Stojadinovic A, Hoos A, Nissan A, et al. Parathyroid neoplasms: clinical, histopathological and tissue microarray-based molecular analysis. Hum Pathol. 2003;34:54-64.
9. Vasef MA, Brynes RK, Sturm M, et al. Expression of cyclin D1 in parathyroid carcinomas, adenomas and hyperplasias: a paraffin immunohistochemical study. Mod Pathol. 1999;12:412-416.
10. Haven CJ, van Puijenbroek M, Karcrien M, et al. Differential expression of the calcium sensing receptor and combined loss of chromosomes 1q and 11q in parathyroid carcinoma. J Pathol. 2004;202:86-94.
11. Bergero N, De Pompa R, Sacerdote C, et al. Galectin-3 expression in parathyroid carcinomas: immunohistochemical study of 26 cases. Hum Pathol. 2005;36:908-914.
12. Carpten JD, Robbins CM, Villablanca A, et al. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet. 2002;32:676-680.
13. Shattuck TM, Valimaki S, Obara T, et al. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med. 2003;349:1722-1729.
14. Howell VM, Haven CJ, Kahnoski K, et al. HRPT2 mutations are associated with malignancy in sporadic parathyroid tumors. J Med Genet. 2003;40:657-663.
15. Haven CJ, Howell VM, Eilers PH, et al. Gene expression of parathyroid tumors: molecular subclassification and identification of the potential malignant phenotype. Cancer Res. 2004;64:7405-7411.
16. Gill AJ, Clarkson A, Gimm O, et al. Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias. Am J Surg Pathol. 2006;30:1140-1149.
17. Tan MH, Morrison C, Wang P, et al. Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. Clin Cancer Res. 2004;10:6629-6637.